Frontlight ResearchEarly access
Kidney cancer trials in Italy
30 of 48 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- Where
- Bari, Bologna, Florence, Meldola, Milan, Padova, Perugia, Rome, Rozzano
- Age
- 18 years and over
- People
- 758 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07489495 · EU 2024-516993-31-00 - Phase 3Taking peopleA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Where
- Arezzo, Bari, Bologna, Florence, Genoa, Milan, Naples, Orbassano, Padova, Parma, Peschiera del Garda, Rome, Rozzano
- Age
- 18 years and over
- People
- 904 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07227402 · EU 2024-517136-21-00 - No phaseTaking peopleClinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
- Where
- Milan
- Age
- 18 years and over
- People
- 124
- Run by
- Niguarda Hospital
See details and how to joinNCT07234409 - Phase 3Taking peopleStudy of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Bari, Florence, Genoa, Lecce, Macerata, Milan, Naples, Padova, Parma, Perugia, Pisa, Rome, Rozzano, Terni, Turin, Verona
- Age
- 18 years and over
- People
- 720 worldwide
- Run by
- Arcus Biosciences, Inc.
See details and how to joinNCT07011719 · EU 2024-515023-11-00 - No phaseTaking peopleStereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer
- Where
- Milan
- Age
- 18 years and over
- People
- 60
- Run by
- IRCCS San Raffaele
See details and how to joinNCT07285538 - Phase 1/2Not yet taking people in ItalyA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Where
- Milan, Naples, Verona
- Age
- 18 years and over
- People
- 474 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07293351 · EU 2026-527163-15-00 - Phase 1Taking peopleKO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Where
- Bologna, Candiolo, Naples, Rozzano, Verona
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00 - Phase 1Taking peopleA Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Where
- Bologna, Milan, Rome, Verona
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07195916 · EU 2025-523130-11-00 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Ancona, Bologna, Florence, Milan, Naples, Ravenna
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 1Not yet taking people in ItalyA Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
- Where
- Roma, Rozzano
- Age
- 18 years and over
- People
- 112 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07848295 - Phase 3Taking peopleCARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
- Where
- Aviano, Bari, Bologna, Brescia, Cremona, Florence, Genoa, Milan, Modena, Naples, Padova, Parma, Pavia, Reggio Emilia, Rome, Terni, Verona
- Age
- 18 years and over
- People
- 1,373 worldwide
- Run by
- Institut Gustave Roussy
See details and how to join2023-503317-29-00 - Phase 2Not yet taking people in ItalyActivity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT MeetURO trial)
- Where
- Milan
- Age
- 18 years and over
- People
- 23
- Run by
- Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2024-511587-93-00 - No phaseTaking peopleIntensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma
- Where
- Aviano
- Age
- 18 years and over
- People
- 216
- Run by
- Centro di Riferimento Oncologico - Aviano
See details and how to joinNCT07805122 - Phase 3Not yet taking people in ItalySequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
- Where
- Alba, Arezzo, Aviano, Bari, Carpi, Cremona, Florence, Latina, Lecce, Legnano, Meldola, Milan, Modena, Naples, Novara, Orbassano, Padova, Palermo, Parma, San Giovanni Rotondo, Turin, Varese
- Age
- 18 years and over
- People
- 500
- Run by
- Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2025-523903-31-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Candiolo, Milan, Naples, Roma, Rozzano, Siena
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1Not yet taking people in ItalyA First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Where
- Rome, Verona
- Age
- 18 years and over
- People
- 281 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07195682 · EU 2025-522543-18-00 - Phase 4Taking peopleIntensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma
- Where
- Aviano, Bolzano
- Age
- 18 years and over
- People
- 216
- Run by
- Centro Di Riferimento Oncologico Di Aviano
See details and how to join2026-525267-40-00 - Phase 2Not yet taking people in ItalyPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Where
- Milan, Padova, Rome
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Advenchen Pharmaceuticals, LLC.
See details and how to joinNCT05363280 · EU 2023-509067-24-01 - Phase 1Not yet taking people in ItalyA Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
- Where
- Rome
- Age
- 18 years to 75 years
- People
- 96
- Run by
- Philogen S.p.A.
See details and how to joinNCT07566897 · EU 2025-522243-17-00 - Phase 1/2Not yet taking people in ItalyA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Where
- Milan, Naples, Rome, Verona
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00 - Phase 4Taking peopleCLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY
- Where
- Arezzo, Asti, Bari, Bergamo, Bologna, Brescia, Catania, Catanzaro, Florence, Frattamaggiore, Lecce, Macerata, Meldola, Milan, Modena, Naples, Novara, Orbassano, Padova, Parma, Perugia, Pisa, Ravenna, Reggio Emilia, Rome, Rozzano, San Giovanni Rotondo, Terni, Trento, Turin, Verona
- Age
- 18 years and over
- People
- 409
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to join2024-517789-41-00 - Phase 2Taking peoplePembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
- Where
- Milan
- Age
- 18 years and over
- People
- 23
- Run by
- Giuseppe Procopio
See details and how to joinNCT06302569 - Phase 4Taking peoplePrimary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
- Where
- Roma
- Age
- 18 years and over
- People
- 409
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06903312 - Phase 2Taking peopleAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Where
- Ancona, Bologna, Meldola, Milan, Padova, Turin
- Age
- 18 years and over
- People
- 497 worldwide
- Run by
- Apollomics Inc.
See details and how to joinNCT03175224 · EU 2024-514542-37-00 - Phase 3WithdrawnA Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- Where
- Candiolo, Catania, Meldola (FC), Milan, Naples, Novara, Pavia, Pisa, Roma
- Age
- 18 years and over
- People
- 413 worldwide
- Run by
- Xynomic Pharmaceuticals, Inc.
See details and how to joinNCT03592472